(Q34182210)

English

Anagrelide: a novel agent for the treatment of myeloproliferative disorders

scientific article

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

title

Anagrelide: a novel agent for the treatment of myeloproliferative disorders (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

31 July 2017

S L Pescatore

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249536

retrieved

31 July 2017

C Lindley

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249536

retrieved

31 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249536

retrieved

31 July 2017

published in

Expert Opinion on Pharmacotherapy

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249536

retrieved

31 July 2017

volume

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249536

retrieved

31 July 2017

issue

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249536

retrieved

31 July 2017

page(s)

537-546

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249536

retrieved

31 July 2017

cites work

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.1.3.537

retrieved

21 January 2018

The effects of anagrelide on human megakaryocytopoiesis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.1.3.537

retrieved

21 January 2018

Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.1.3.537

retrieved

21 January 2018

Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.1.3.537

retrieved

21 January 2018

Identifiers

DOI

10.1517/14656566.1.3.537

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249536

retrieved

31 July 2017

PubMed publication ID

11249536

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249536

retrieved

31 July 2017

(Q34182210)

Anagrelide: a novel agent for the treatment of myeloproliferative disorders

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)